Advances in Early Alzheimer’s Detection
The prevalence of Alzheimer’s disease (AD) is rapidly increasing as individual life spans across the world […]
The prevalence of Alzheimer’s disease (AD) is rapidly increasing as individual life spans across the world […]
For this week’s Biorasi Spotlight, meet Mari Heghinian, PhD, Manager of Program Development at Biorasi, LLC.
1. […]
If you had to pick one buzzword that perfectly encapsulated the current latest and greatest in […]
MIAMI, FL – ( April 12, 2017) – Biorasi, LLC. announced today that their Vice President […]
This introduction marks the launch of a series of White Papers dealing with the optimization of Clinical Endpoint ANDA Programs for the generics and specialty pharmaceutical industry.
CNS trials especially can become mired down and derailed by a too-low enrollment rate, and the culprit is usually poor venue and site planning and selection. Patient Enrollment Needs To Be Strategic, Not Just Tactical. Learn more in this case study
Ensuring timely, quality, cost-effective execution of ESRD clinical trials requires a research organization to leverage the right people, processes, and technology infrastructure to overcome the trial complexities inherent in ESRD drug development. This white paper explores the complexities of running clinical trials in advanced CKD and the ESRD populations and looks at the solutions that can be employed to overcome challenges.
Over the next five years, the purchase and production of biosimilar […]
The study is behind schedule. Enrollment is lagging. The protocol is too complicated. Approximately 80 percent of […]